New Formulations of Acyclothymidine Dinucleosides Reduce Damaging Effects of Ultraviolet Radiation in an Ex Vivo Skin Model

Abbas Raza, Christine D Dreis, Leon Kircik, Naiem T. Issa, Robert Vince

Research output: Contribution to journalArticlepeer-review

Abstract

The greatest risk factor for skin cancer is exposure to ultraviolet (UV) rays of the sun. Among the 3 types of solar radiation (UVA, UVB, UVC), UVB rays are most commonly associated with skin cancer. UVB exposure promotes the formation of cyclobutane pyrimidine dimers (CPDs) in the DNA of cells in the epidermal skin layers, which can lead to mutations as DNA repair machinery attempts to repair the damage. These mutations can lead directly to skin carcinogenesis. Previous studies in animal and in human ex vivo skin models have shown that topical application of acyclothymidine dinucleosides protects DNA from UV-induced damage by preventing the formation of CPDs and helps initiate repair through the activation of DNA repair enzymes. Here we review the biological evidence leading to the development and formulation of ProteXidine™ (Topix Pharmaceuticals, Inc., Amityville, NY), as a UV protective agent for topical human application. We also provide clinical data pertaining to four ProteXidine™ formulations (test materials 1-4) tested for their abilities to reduce CPDs in an ex vivo human skin tissue model.

Original languageEnglish (US)
Pages (from-to)953-956
Number of pages4
JournalJournal of Drugs in Dermatology
Volume23
Issue number11
DOIs
StatePublished - Nov 2024

Bibliographical note

Publisher Copyright:
Copyright © 2024.

PubMed: MeSH publication types

  • Journal Article
  • Review

Fingerprint

Dive into the research topics of 'New Formulations of Acyclothymidine Dinucleosides Reduce Damaging Effects of Ultraviolet Radiation in an Ex Vivo Skin Model'. Together they form a unique fingerprint.

Cite this